The revenue miss vs consensus and deepening stockholders' equity deficit with a second NYSE non-compliance notice are the primary bearish signals. Monitor the June 7 compliance plan deadline and any further equity dilution from the warrant exchange or additional offerings. The May 2026 $5M offering provides near-term cash but does not resolve the listing risk.
Price Chart
Executive Summary
Picard Medical reported Q1 2026 revenue of $1.2M (85% YoY growth), gross profit turned positive at $0.3M (24% margin vs -58% a year ago), but net loss widened to $7.6M including non-cash charges. The company reduced debt significantly but received a second NYSE American non-compliance notice for stockholders' equity deficit of $(1.4)M, with a compliance plan due by June 7, 2026.
Key Financial Metrics
Key Facts
- Revenue grew 85% YoY to $1.2M, product revenue up 54% to $0.9M, Freedom Driver rental revenue grew to $0.2M from $7,000
- Gross profit turned positive at $0.3M (24% margin) vs gross loss of $0.4M (-58%) in Q1 2025
- Net loss was $7.6M, including significant non-cash charges related to debt settlement and fair value adjustments
- Repaid ~$7.4M of senior secured note principal in cash, settled $2.1M via 1.4M shares, reduced related-party debt by ~$0.9M
- Remaining Senior Secured Note balance reduced to ~$1.3M
- Received second NYSE American non-compliance notice for stockholders' equity deficit of $(1.4)M as of March 31, 2026
- Must submit compliance plan by June 7, 2026; '.BC' indicator appended to ticker
- Completed public offering in May 2026 raising $5.0M gross proceeds
- Entered warrant exchange replacing 7.0M warrants at $2.675 exercise with 10.0M new warrants at $0.35 exercise
Financial Impact
Revenue $1.2M vs consensus $1.6M (miss); EPS not reported vs consensus $-0.03; net loss $7.6M; debt reduced by ~$10.4M total; stockholders' equity deficit $(1.4)M
Risk Factors
- Potential delisting from NYSE American if compliance plan is not accepted or executed by November 8, 2027
- Continued net losses and negative stockholders' equity may require further dilutive financing
- Warrant exchange creates 10M new shares at $0.35 exercise, adding dilution overhang
- Revenue of $1.2M missed $1.6M consensus, indicating slower-than-expected commercial ramp
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299176 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $6.43 | awaiting T+60 | — | $6.83 (+6.22%) |
Oct 22, 2026 5d ago | S-3 | $7.37 | awaiting T+60 | — | $6.83 (+7.33%) |
Oct 6, 2026 21d ago | 8-K | $8.74 | awaiting T+60 | — | $6.83 (+21.85%) |
Jul 27, 2026 13w ago | 8-K | $0.0878 $0.2096 | ▲ +138.72% | ▲ +134.67% | $6.83 (+7679.04%) |
Jul 15, 2026 14w ago | DEFA14A | $0.1600 $0.1896 | ▲ +18.50% | ▲ +14.79% | $6.83 (+4168.75%) |
Jul 8, 2026 15w ago | DEFA14A | $0.1500 $0.0864 | ▼ −42.40% | ▼ −44.89% | $6.83 (+4453.33%) |
Jul 2, 2026 16w ago | 8-K / 425 | $0.1694 | awaiting T+60 | — | $6.83 (+3931.88%) |
Jun 29, 2026 17w ago | 8-K | $0.1559 $0.0910 | ▼ −41.63% | ▼ −45.25% | $6.83 (+4281.01%) |
Jun 2, 2026 21w ago | Press Release | $13.50 | awaiting T+60 | — | $6.83 (−49.41%) |
Jun 2, 2026 21w ago | 8-K | $13.50 | awaiting T+60 | — | $6.83 (+49.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers